Biomea Fusion (BMEA) to Release Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) will likely be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Biomea Fusion (NASDAQ:BMEA) last posted its earnings results on Monday, March 31st. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.19. On average, analysts expect Biomea Fusion to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Biomea Fusion Trading Up 8.7 %

Shares of BMEA stock opened at $2.12 on Friday. The firm has a market capitalization of $79.65 million, a price-to-earnings ratio of -0.53 and a beta of -0.07. The business’s 50-day moving average price is $3.10 and its 200-day moving average price is $5.80. Biomea Fusion has a 12 month low of $1.86 and a 12 month high of $13.66.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Biomea Fusion in a research report on Monday, March 31st. D. Boral Capital reiterated a “buy” rating and set a $16.00 price target on shares of Biomea Fusion in a report on Wednesday, March 19th. Oppenheimer set a $10.00 price objective on shares of Biomea Fusion in a research note on Monday, March 24th. Finally, Barclays lowered their target price on Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a research report on Wednesday. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Biomea Fusion currently has an average rating of “Buy” and a consensus target price of $23.91.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.